Selectin blockade plus therapy with low-dose sirolimus and cyclosporin A prevent brain death-induced renal allograft dysfunction

American Journal of Transplantation

Volumn 5, Issue 4 I, 2005, Pages 662-670

  Gasser, Martin ^a,b   Waaga Gasser, Ana Maria ^a,b   Grimm, Michael W ^b   Grimm, Martin R ^b   Lenhard, Miriam S ^a   Kist Van Holthe, Joana E ^a   Laskowski, Igor ^a   Shaw, Gray D ^c   Thiede, Arnulf ^b   Hancock, Wayne W ^d   Tilney, Nicholas L ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c PFIZER INC   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Brain death; Chronic rejection; Ischemia reperfusion injury; P selectin glycoprotein ligand 1

Indexed keywords

CYCLOSPORIN A; P SELECTIN GLYCOPROTEIN LIGAND 1; RAPAMYCIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN DETECTION; ARTICLE; BRAIN DEATH; CONTROLLED STUDY; DISEASE MODEL; EARLY DIAGNOSIS; GRAFT SURVIVAL; HISTOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT REJECTION; LONG TERM CARE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SURVIVAL;

ANIMALS; BRAIN DEATH; CREATININE; CYCLOSPORINE; CYTOKINES; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; PROTEINURIA; RATS; RATS, INBRED F344; SELECTINS; SIROLIMUS; TIME FACTORS;

EID: 20144389110     PISSN: 16006135     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2005.00763.x     Document Type: Article

References (33)

1. Bennett WM, DeMattos A, Meyer MM, Andoh T, Barry JM. Chronic cyclosporine nephropathy: the Achilles' heel of immunosuppressive therapy. Kidney Int 1996; 50: 1089-1100.
2. Stepkowski SM, Napoli KL, Wang ME, Qu X, Chou TC, Kahan BD. Effects of the pharmacokinetic interaction between orally administered SRL and cyclosporine on the synergistic prolongation of heart allograft survival in rats. Transplantation 1996; 62: 986-994.
3. Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier-Kriesche HU, Van Buren CT. Immunosuppressive effects and safety of a SRL/cyclosporine combination regimen for renal transplantation. Transplantation 1998; 66: 1040-1046.
4. Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J. SRL reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Transplantation 1999; 68: 1526-1532.
5. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a SRL/cyciosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271-280
6. Gonwa TA, Hricik DE, Brinker K et al. Improved renal function in SRL-treated renal transplant patients after early cyclosporine elimination. Transplantation 2002; 74: 1560-1567.
7. Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J. SRL allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777-786.
8. Groth CG, Backman L, Morales JM et al. SRL (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. SRL European Renal Transplant Study Group. Transplantation 1999; 67: 1036-1042.
9. Lieberthal W, Fuhro R, Andry CC et al. Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells. Am J Physiol Renal Physiol 2001; 281: 693-706.
10. Podder H, Stepkowski SM, Napoli KL et al. Pharmacokinetic interactions augment toxicities of SRL/cyclosporine combinations. J Am Soc Nephrol 2001; 12: 1059-1071.
11. Takada M, Nadeau KC, Hancock WW et al. Effects of explosive brain death on cytokine activation of peripheral organs in the rat. Transplantation 1998; 65: 1533-1542.
12. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med 1995; 333: 333-336.
13. Takada M, Nadeau KC, Shaw GD, Marquette KA, Tilney NL. The cytokine-adhesion molecule cascade in ischemia/reperfusion injury of the rat kidney. Inhibition by a soluble P-selectin ligand. J Clin Invest 1997; 99: 2682-2690.
14. Hancock WH, Whitley WD, Tullius SG et al. Cytokines, adhesion molecules, and the pathogenesis of chronic rejection of rat renal allografts. Transplantation 1993; 56: 643-650.
15. Shivalkar B, Van Loon J, Wieland W et al. Variable effects of explosive or gradual increase of intracranial pressure on myocardial structure and function. Circulation 1993; 87: 230-239.
16. Pratschke J, Wilhelm MJ, Kusaka M et al. Accelerated rejection of renal allografts from brain-dead donors. Ann Surg 2000; 232: 263-271.
17. Tilney NL, Guttmann RD. Effects of initial ischemia/reperfusion injury on the transplanted kidney. Transplantation 1997; 64: 945-947.
18. McEver RP, Cummings RD. Perspectives series: cell adhesion in vascular biology. Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest 1997; 100: 485-491.
19. McEver RP, Cummings RD. Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest 1997; 100: 97-103.
20. Somers WS, Tang J, Shaw GD, Camphausen RT. Insights into the molecular basis of leukocyte tethering and rolling revealed by structures of P- and E-selectin bound to SLe(X) and PSGL-1. Cell 2000; 103: 467-479.
21. Gasser M, Waaga AM, Kist-Van Holthe JE et al. Normalization of brain death-induced injury to rat renal allografts by recombinant soluble P-selectin glycoprotein ligand. J Am Soc Nephrol 2002; 13: 1937-1945.
22. Pratschke J, Wilhelm MJ, Kusaka M, Laskowski I, Tilney NL. A model of gradual onset brain death for transplant-associated studies in rats. Transplantation 2000; 69: 427-430.
23. Schmid C, Heemann U, Azuma H, Tilney NL. Rapamycin inhibits transplant vasculopathy in long-surviving rat heart allografts. Transplantation 1995; 60: 729-733.
24. Stepkowski SM, Chen H, Daloze P, Kahan BD. Prolongation by rapamycin of heart, kidney, pancreas, and small bowel allograft survival in rats. Transplant Proc 1991; 23: 507-508.
25. Vu MD, Qi S, Xu D et al. Synergistic effects of mycophenolate mofetil and SRL in prevention of acute heart, pancreas, and kidney allograft rejection and in reversal of ongoing heart allograft rejection in the rat. Transplantation 1998; 66: 1575-1580.
26. Frenette PS, Denis CV, Weiss L et al. P-Selectin glycoprotein ligand 1 (PSGL-1) is expressed on platelets and can mediate platelet-endothelial interactions in vivo. J Exp Med 2000; 191: 1413-1422.
27. Sako D, Comess KM, Barone KM, Camphausen RT, Cumming DA, Shaw GD. A sulfated peptide segment at the amino terminus of PSGL-1 is critical for P-selectin binding. Cell 1995; 83: 323-331.
28. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocynate-phenol-chloroform extraction. Anal Biochem 1987; 162: 156-159.
29. Cecka JM. The UNOS renal transplant registry. Clin Transpl 2002; 1-20.
30. Kahan BD. Efficacy of SRL compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000; 356: 194-202.
31. Avlonitis VS, Fisher AJ, Kirby JA, Dark JH. Pulmonary transplantation: the role of brain death in donor lung injury. Transplantation 2003; 75: 1928-1933.
32. Evangelista V, Manarini S, Sideri R et al. Platelet/ polymorphonuclear leukocyte interaction: P-selectin triggers protein-tyrosine phosphorylation- dependent CD11b/CD18 adhesion: role of PSGL-1 as a signaling molecule. Blood 1999; 93: 876-885.
33. Hayward R, Campbell B, Shin YK, Scalia R, Lefer AM. Recombinant soluble P-selectin glycoprotein ligand-1 protects against myocardial ischemic reperfusion injury in cats. Cardiovasc Res 1999; 41: 65-76.